Brunani Amelia, Palli Domenico, Salvini Simonetta, Masala Giovanna, Vallone Luciana, Barantani Eros, Liuzzi Antonio
Department of Endocrinology and Metabolic Diseases, Ospedale San Giuseppe, IRCCS, Istituto Auxologico Italiano, Piancavallo (Verbania), Italy.
Eur J Nutr. 2002 Aug;41(4):183-5. doi: 10.1007/s00394-002-0371-5.
Morbid obesity has been associated with increased mortality.
We evaluated the risk of short- (2 years) and long-term (10 years) mortality in two consecutive series of Italian morbidly obese patients hospitalized in a Metabolic Unit.
The vital status of 569 patients (435 females and 134 males, BMI 44.4 kg/m(2), age 46.1 years), first admitted for clinical treatment in two separate periods (1988 and 1996), was ascertained in 1999.
Twenty-seven deaths were identified and compared with expected deaths according to mortality rates in the Italian population, to estimate the standardized mortality ratio (SMR). In the first two years after admission only 3 deaths were observed and the SMR tended to be reduced (SMR = 0.5, 95 % CI 0.1-1.5). In contrast, the long-term follow-up showed a significantly elevated risk of death (SMR = 1.6, 95 % CI 1.1-2.4).
The follow-up of this Italian prevalent cohort confirm that morbid obesity is associated with increased mortality. The observed SMR might have been attenuated by inclusion in our study of subjects with relatively good health conditions, who are possibly more representative of the general obese population than subjects affected by important obesity-related complications, observed in other studies. The excess risk was not evident in the first two years after clinical treatment.
病态肥胖与死亡率增加相关。
我们评估了在代谢科住院的两组连续的意大利病态肥胖患者短期（2年）和长期（10年）死亡风险。
确定了569例患者（435例女性和134例男性，BMI 44.4 kg/m²，年龄46.1岁）的生命状态，这些患者在两个不同时期（1988年和1996年）首次入院接受临床治疗，时间为1999年。
确定了27例死亡病例，并根据意大利人群的死亡率与预期死亡病例进行比较，以估计标准化死亡率（SMR）。入院后的头两年仅观察到3例死亡，SMR有降低趋势（SMR = 0.5，95%CI 0.1 - 1.5）。相比之下，长期随访显示死亡风险显著升高（SMR = 1.6，95%CI 1.1 - 2.4）。
对这个意大利现患队列的随访证实病态肥胖与死亡率增加相关。我们的研究纳入了健康状况相对较好的受试者，这可能使观察到的SMR有所降低，这些受试者可能比其他研究中观察到的受重要肥胖相关并发症影响的受试者更能代表一般肥胖人群。临床治疗后的头两年，额外风险并不明显。
